CyberKnife Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global CyberKnife Market Trends and Insights

Rising Cancer Burden and Treatment Demand

The CyberKnife market is gaining support from the steady rise in cancer volume and case complexity across major care systems. The World Health Organization said annual global cancer cases are expected to exceed 35 million by 2050, which keeps long-term demand strong for precise radiation platforms that can absorb more patients without a matching increase in treatment infrastructure^{[1]World Health Organization, “Global Cancer Burden Growing, Amidst Mounting Need for Services,” WHO, who.int}. This demand is especially relevant for brain metastases, vertebral metastases, and prostate cancer, where longer survival in primary oncology is increasing the number of patients who need focused local treatment. Australia’s cancer diagnoses are projected to rise from 212,332 cases to 318,285 by 2045, which supports the business case for expanding access to high-precision treatment networks. Austria also remains under-supplied in radiotherapy equipment, with availability 27% below the EU average and 34% below economic peers, which creates room for new CyberKnife market installations in under-served regions. As these supply gaps persist, the CyberKnife market is likely to benefit most in locations where cancer demand is rising faster than radiotherapy capacity.

Preference for Non-Invasive and Organ-Sparing Treatment

The CyberKnife market is also benefiting from the broader preference for non-invasive care that avoids surgery when clinical outcomes are comparable. CyberKnife’s Synchrony real-time motion-tracking capability helps clinicians treat thoracic, hepatic, and spinal targets with continuous adjustment for patient movement, which broadens its use beyond frame-based intracranial treatment. A 2025 long-term study of vestibular schwannoma patients reported 89.3% local control and 97.1% overall survival at 25 years after CyberKnife treatment, which reinforces confidence in durable organ-sparing management. A 2025 clinical study from Peking Union Medical College Hospital also found highly accurate dose delivery with minimal damage to surrounding tissue in pituitary adenoma and lung adenocarcinoma vertebral metastasis cases, which supports broader extracranial use. As a result, the CyberKnife market is gaining from a treatment preference that values precision, tissue preservation, and recovery outside the operating room.

Expansion of Outpatient and Ambulatory Radiosurgery Delivery

The CyberKnife market is moving closer to outpatient care models as hospitals and physician groups look for more efficient ways to deliver high-value oncology services. Bundled payment models and value-based reimbursement create pressure to reduce inpatient use, which makes ambulatory treatment settings more attractive for eligible radiation cases. CyberKnife fits this shift because its 1 to 5 session treatment profile allows faster scheduling and removes the long multi-week treatment pattern associated with conventional radiotherapy. In July 2025, Asian Hospital in the Philippines installed the country’s first CyberKnife S7 system, and in October 2025 Unio Specialty Care launched community-based CyberKnife S7 treatment in San Diego, showing that deployment is moving beyond major academic hubs. Vietnam’s social health insurance now covers CyberKnife S7 treatment, which lowers the affordability barrier and improves the case for broader utilization beyond elite private settings. This shift is important because the CyberKnife market can expand faster when treatment access is no longer limited to large tertiary campuses.

Faster Adoption of Hypofractionated Treatment Pathways

The CyberKnife market is also supported by the wider use of hypofractionated treatment plans that shorten therapy timelines without giving up local control. A 2026 peer-reviewed cohort study in Radiation Oncology reported durable local control in brain metastases treated with CyberKnife fractionated stereotactic radiotherapy, while also identifying tumor volume and prior surgery as important predictors of outcome. The platform’s ability to deliver prostate treatment in 5 sessions instead of 40 conventional sessions improves treatment vault productivity and strengthens the return profile of each installed system. This matters more in emerging markets where capital outlays of USD 5 million to USD 7 million need strong utilization to be justified. Post-surgical resection cavity treatment is also gaining ground, with a 2025 study reporting 1-year local control rates of 93% for stereotactic radiosurgery after brain metastasis resection. As these shorter-course protocols become more accepted, the CyberKnife market stands to benefit from higher throughput and a broader set of clinically validated use cases.

High Capital Cost and Service Intensity

The CyberKnife market still faces a major barrier from the high upfront cost of system acquisition and the ongoing cost of support after installation. A typical system costs USD 5 million to USD 7 million before shielding construction and commissioning, which limits new projects to well-capitalized academic and tertiary providers. This burden becomes even more important after installation because service contracts, upgrades, and maintenance add recurring obligations over the asset life. Accuray reported that service revenue rose 3% year over year to USD 169.1 million in the first 9 months of fiscal 2026, while product revenue fell 21%, which shows how a slower capital cycle and a maturing installed base can weigh on fresh placements while raising service dependence. In Mexico, IMSS spent USD 8.7 million, to commission its first CyberKnife system in December 2025, which underlines how large these projects are even for public institutions. Because of this, the CyberKnife market remains concentrated in health systems that can absorb both capital and long-term service intensity.

Prior Authorization and Reimbursement Friction

The CyberKnife market is also constrained by reimbursement delays and payer scrutiny, especially in North America. An ASTRO survey published in June 2025 found that 92% of radiation oncologists said prior authorization delayed treatment initiation, while 68% said those delays extended beyond 1 week. CyberKnife procedures face an additional layer of review because CMS uses dedicated HCPCS codes G0339 and G0340 for robotic image-guided radiosurgery, and some Medicare Advantage plans have reportedly denied these claims at elevated rates compared with other radiation therapy services. A 2024 peer-reviewed review in Advances in Radiation Oncology also found that radiation oncology carried the highest prior authorization burden across medical specialties, with stereotactic body radiation therapy seeing a disproportionate impact^{[2]“The Burden of Insurance Prior Authorization on Cancer Care, A Review of Evidence From Radiation Oncology,” Advances in Radiation Oncology, advancesradonc.com}. CMS then finalized further valuation changes for radiation therapy delivery codes in the CY 2026 Physician Fee Schedule, which added more administrative recalibration during the current operating cycle. Until approval timelines improve, the CyberKnife market will continue to face revenue timing pressure even in clinically established settings.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Services Growth Reshapes the Revenue Architecture

The CyberKnife System segment held 48.31% of the CyberKnife market share in 2025, which kept hardware as the largest product category in the CyberKnife market. Services, however, are projected to grow at an 8.38% CAGR through 2031, making them the fastest-rising layer of the CyberKnife market by product type. This change matters because installed systems generate recurring revenue through preventive maintenance, remote diagnostics, training, and software upgrades even when new hardware orders slow. Accuray reported service revenue of USD 169.1 million in the first 9 months of fiscal 2026, up 3% year over year, while product revenue declined, which supports the view that the installed base is becoming more important to the CyberKnife market than single equipment sales^{[3]Accuray Incorporated, “Accuray Reports Fiscal 2026 Third Quarter Financial Results,” Accuray Investor Relations, accuray.com}.

Software is still the most dynamic layer inside the broader platform stack because it supports planning, adaptive delivery, and faster commissioning. Accuray received NMPA approval in China for the Accuray Precision Treatment Planning System in June 2024, and in September 2025 launched the Stellar solution, which brought adaptive radiotherapy capabilities together with CyberComm commissioning tools. That launch shows how the CyberKnife industry is moving toward a model where software, service, and workflow integration deepen customer retention after the initial sale. It also means procurement teams are placing more weight on lifetime ownership cost than on unit price alone. In practical terms, the CyberKnife market size for services is projected to expand at 8.38% CAGR through 2031, which signals that recurring post-sale revenue is becoming central to vendor economics.

By Indication: Vascular Malformation Emerges as a High-Value Growth Corridor

Tumor and cancer treatment accounted for 85.24% share in 2025, which made oncology the clear foundation of the CyberKnife market by indication. Prostate cancer, lung cancer, brain metastases, and spinal tumors remain the highest-volume use cases because they fit the platform’s need for accurate dose delivery around critical structures. Long-term clinical data continue to support that position, with reported 10-year disease-free survival of 93.7% in localized prostate cancer treated with CyberKnife. This strong oncology base gives the CyberKnife market a broad demand floor across both intracranial and extracranial treatment settings.

Vascular malformation remains smaller in absolute revenue but is forecast to grow at an 8.52% CAGR through 2031, which makes it the fastest-growing indication in the CyberKnife market. A 2025 study in Strahlentherapie und Onkologie reported 5-year obliteration rates of 85.2% for Spetzler-Martin grade I and II cerebral arteriovenous malformations, which supports radiosurgery as a strong treatment option in selected cases. A 2025 meta-analysis in the Journal of Clinical Neuroscience also found that stereotactic radiosurgery alone delivered higher AVM obliteration rates than combined embolization plus radiosurgery, which lowers some of the procedural friction that previously shaped treatment sequencing. Other uses such as trigeminal neuralgia, functional neurosurgery, and cardiac arrhythmias remain smaller today but are strategically important for future volume. FV Hospital’s May 2025 deployment in Vietnam included positioning for cardiac arrhythmia treatment as well as vascular malformations, which shows how the CyberKnife industry is testing expansion beyond its core oncology base.

By End User: Ambulatory Centers Redefine the Access Frontier

Hospitals and academic medical centers held 75.52% share in 2025, which kept them as the leading end-user group in the CyberKnife market. Their lead reflects the need for high capital investment, shielded vaults, and multidisciplinary clinical teams that large institutions are better able to organize and fund. This concentration has been reinforced by the fact that many early deployments were made in tertiary settings where complex oncology volumes were already established. Even so, the center of gravity inside the CyberKnife market is starting to shift as other care settings become operationally viable.

Ambulatory and outpatient radiosurgery centers are projected to grow at a 9.25% CAGR through 2031, which makes them the fastest-growing end-user group in the CyberKnife market. This shift is tied to shorter treatment schedules, improved commissioning speed through CyberComm, and the ability of community-based providers to raise vault utilization with hypofractionated treatment patterns. Unio Specialty Care’s October 2025 installation in San Diego shows that physician-led and private-equity-backed platforms are now willing to place CyberKnife outside quaternary academic centers. Independent radiotherapy centers also sit in an important middle tier, especially where oncology delivery is partly privatized or regionally dispersed. Mexico’s IMSS expected a daily schedule of 30 to 35 radiosurgery sessions after launch, which shows how throughput assumptions now shape adoption decisions at the institutional level.

Geography Analysis

North America held 45.22% share in 2025, which gave the region the largest position in the CyberKnife market and the most established operating environment. The United States remained the anchor because of its large installed base, established CMS reimbursement codes for robotic image-guided radiosurgery, and long history of high-technology oncology procurement. Even in this mature setting, access is still expanding into community care, as shown by the October 2025 San Diego CyberKnife S7 launch, which was described as one of only 2 sites in California and the only one in Southern California. Mexico remained a smaller market, but its December 2025 public-sector installation through IMSS marked a meaningful regional step because it showed that government-backed procurement can support CyberKnife market development outside high-income systems.

Europe remains more concentrated by country and by site type, with academic centers playing a leading role in the CyberKnife market. Germany continued to be the region’s most established base, and Charité Berlin remained a prominent university hospital site for CyberKnife treatment. Austria added a fresh point of expansion in May 2025 when the CyberKnife Center Salzburg started SRS and SBRT patient treatments using the CyberKnife S7 system. That project also highlighted a structural supply gap, since Austria’s radiotherapy equipment availability remained 27% below the EU average, which supports room for further CyberKnife market growth in under-equipped systems. Across the region, compliance under EU medical device rules continues to add cost and operating discipline for both vendors and center operators.

Asia-Pacific is projected to grow at a 9.65% CAGR through 2031, which makes it the fastest-expanding regional block in the CyberKnife market. China’s January 2025 NMPA approval of the CyberKnife S7 system opened a much larger hospital base to next-generation deployment and improved the platform’s access to one of the world’s largest cancer care systems. In India, installations in Lucknow and Western Uttar Pradesh show that adoption is moving beyond top-tier metro centers, although regulatory approvals still shape commissioning timelines. Australia also became a visible growth market after the October 2025 Melbourne launch through a joint venture between 5D Clinics and Icon Group, with plans to expand across the East Coast. In the Middle East and Africa, Tawam Hospital introduced the first CyberKnife S7 deployment in Abu Dhabi and Kenya commissioned the first CyberKnife in sub-Saharan Africa, while South America remained early stage with Brazil and Colombia already active and Mexico joining the regional installed base in 2025.